Literature DB >> 10858512

The envenomation syndrome caused by the Australian Red-bellied Black Snake Pseudechis porphyriacus.

J Pearn1, B McGuire, L McGuire, P Richardson.   

Abstract

The Australian elapids inject venom which is characteristic of each species; and which cause characteristic and specific envenomation syndromes in human victims of snakebite. Because many of the medically significant Australian elapids look similar, when glimpsed in the field by snakebite victims, defining human envenomation syndromes with secure species identification has been a slow process. Correlations between securely identified species and the human envenomation syndromes which they produce are still evolving. The genus Pseudechis is the most widespread in Australia of the dangerous Australian elapid genera; and P. porphyriacus, the Red-bellied Black Snake, was the first terrestrial Australian elapid to be described and illustrated and the first to be the subject of experimental study. We present here five previously unreported cases of human envenomation in which the species diagnosis is secure. From these and with the perspective of a selected literature review, we describe the full envenomation syndrome of this species. Until the development of the Commonwealth Serum Laboratories' Venom Detection Kit in 1979 and the occasional case report of victims of securely identified species, envenomation syndromes for most Australian snake species have remained indeterminate, because of the lack of professional expertise in the identification of the species involved. Symptoms of the P. porphyriacus envenomation syndrome include those of bite-site pain, nausea and vomiting, generalised pruritus, chest pain, prostration and abnormalities of taste and smell. Signs include local necrosis and scarring of tissue at the bite-site, gross inflammation of surrounding tissues and, at least in one case, epilepsy. Although envenomation by the Red-bellied Black Snake is not lethal in adults, the correct therapy is Tiger Snake antivenom, administered with judgement, taking into account knowledge of the specific envenomation syndrome of this species and the clinical status of the victim.

Entities:  

Mesh:

Year:  2000        PMID: 10858512     DOI: 10.1016/s0041-0101(00)00102-1

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  6 in total

Review 1.  Venomous and poisonous Australian animals of veterinary importance: a rich source of novel therapeutics.

Authors:  Margaret C Hardy; Jonathon Cochrane; Rachel E Allavena
Journal:  Biomed Res Int       Date:  2014-07-21       Impact factor: 3.411

Review 2.  Long-term Effects of Snake Envenoming.

Authors:  Subodha Waiddyanatha; Anjana Silva; Sisira Siribaddana; Geoffrey K Isbister
Journal:  Toxins (Basel)       Date:  2019-03-31       Impact factor: 4.546

Review 3.  A review of 91 canine and feline red-bellied black snake (Pseudechis porphyriacus) envenomation cases and lessons for improved management.

Authors:  M K Wun; A M Padula; R M Greer; E M Leister
Journal:  Aust Vet J       Date:  2022-03-23       Impact factor: 1.343

Review 4.  Neurotoxicity in snakebite--the limits of our knowledge.

Authors:  Udaya K Ranawaka; David G Lalloo; H Janaka de Silva
Journal:  PLoS Negl Trop Dis       Date:  2013-10-10

5.  Venom of the Red-Bellied Black Snake Pseudechis porphyriacus Shows Immunosuppressive Potential.

Authors:  Rachael Y M Ryan; Viviana P Lutzky; Volker Herzig; Taylor B Smallwood; Jeremy Potriquet; Yide Wong; Paul Masci; Martin F Lavin; Glenn F King; J Alejandro Lopez; Maria P Ikonomopoulou; John J Miles
Journal:  Toxins (Basel)       Date:  2020-10-26       Impact factor: 4.546

6.  Perceptions, awareness on snakebite envenoming among the tribal community and health care providers of Dahanu block, Palghar District in Maharashtra, India.

Authors:  Itta Krishna Chaaithanya; Dipak Abnave; Himmatrao Bawaskar; Ujwal Pachalkar; Sandip Tarukar; Neha Salvi; Prabhakar Bhoye; Arun Yadav; Smita D Mahale; Rahul K Gajbhiye
Journal:  PLoS One       Date:  2021-08-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.